Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
- Initial EVX-01 Phase 2 data confirms the strong Phase 1 results
- After undergoing EVX-01 treatment, a significant and continuous tumor reduction was observed in a metastatic melanoma patient with initial progressive disease
COPENHAGEN, Denmark, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in the development of AI-Immunology™ powered vaccines, is pleased to announce initial results from the EVX-01 Phase 2 clinical trial, confirming previous successful Phase 1 findings. A comprehensive clinical update will be presented at the Society for Immunotherapy of Cancer (SITC) 38th annual meeting, taking place in San Diego, California, from November 1-5, 2023.
Key highlights of the initial Phase 2 results for the first five metastatic melanoma patients treated with EVX-01 include:
- Phase 2 data confirm the favorable safety profile of EVX-01 observed in the Phase 1 trial
- Promising immunological and clinical outcomes align with the Phase 1 outcomes
- Upon EVX-01 treatment, a pronounced and ongoing tumor reduction was observed in a patient with progressive disease
- Phase 2 data confirms Evaxion’s AI-Immunology™ platform’s ability to identify therapeutically relevant cancer vaccine targets
Christian Kanstrup, CEO of Evaxion, stated, “We firmly believe that our AI-Immunology™ platform has the potential to revolutionize the field of oncology and infectious diseases. Today’s update underscores its promise in immuno-oncology, with our EVX-01 vaccine safely eliciting robust immune responses in all patients. Notably, a pronounced tumor reduction in a metastatic patient with initial progressive disease following EVX-01 treatment offers hope for those with life-threatening cancer. We are looking forward to discussing these results with potential partners.”
Join us at the SITC meeting to explore the poster titled “Effects of an AI-generated personalized neopeptide-based immunotherapy, EVX-01, in combination with pembrolizumab in patients with metastatic melanoma. A clinical trial update”, presented on Saturday, November 4, between 9 a.m. - 8:30 p.m. PDT.
Additionally, don’t miss an in-depth presentation of Evaxion’s EVX-01 Phase 2 clinical results by joining an online webinar featuring the study’s principal investigator, Professor Adnan Khattak, held on November 8 at 11:30 a.m. EST. To register for the event, please follow this link.
Earlier this year, Evaxion reported a successful Phase 1 clinical trial for EVX-01 in combination with a checkpoint inhibitor. The trial demonstrated a 67% clinical response rate while meeting safety standards and reporting only mild adverse events. Further, high-quality neoantigens predicted by AI-Immunology™ were associated with longer progression-free survival. To learn more, please read here.
About EVX-01 Phase 2 Clinical Trial
EVX-01 is Evaxion’s lead clinical asset and constitutes a peptide-based personalized cancer vaccine. The Phase 2 clinical study is a self-sponsored open-label, single-arm, multi-center trial carried out in collaboration with Merck Sharp & Dohme LLC, and together with leading principal investigators and research centers from Italy and Australia aims at evaluating the efficacy and safety of EVX-01 vaccination in combination with anti-PD1 treatment (pembrolizumab) in treatment-naive patients with metastatic or unresectable malignant stage III or IV melanoma. More information can be accessed under clinical trial ID NCT05309421.
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform: AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from the worldwide ongoing COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia and the Middle East; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
Source: Evaxion BiotechTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Alternus Energy Reports Third Quarter 2023 Financial Results28.11.2023 14:30:00 CET | Press release
DUBLIN, Ireland, Nov. 28, 2023 (GLOBE NEWSWIRE) -- International Renewable Independent Power Producer (IPP) Alternus Energy Group Plc (OSE: ALT) (the “Company” or “Alternus”) today announced unaudited U.S. GAAP financial results for the third quarter of 2023 under the US GAAP format. Q3 2023 Highlights Power production decreased by 5.4% YoY to 157 MWh due primarily to weather variances in Poland and the Netherlands.Revenue decreased by $1.9 million (15.3%) to $10.5 million compared to the same reporting period last year primarily because of lower electricity pricing in Poland and from lower irradiation levels due to seasonal weather conditions in Poland and the Netherlands.Gross profit increased by $0.5 million (6.4%) to $8.3 million resulting in gross margin of 79.0% as reduced revenues were offset by tightly controlled project operating costs.Selling and general expenses increased by $1 million (41%) YoY as the company grew personnel and infrastructure to drive development activities
Cellebrite Showcases Innovations in Digital Intelligence at Milipol 202328.11.2023 14:30:00 CET | Press release
Cellebrite demonstrates how agencies can increase productivity of digital investigations by making them smarter, more efficient and defensible TYSONS CORNER, Va. and PETAH TIKVA, Israel and PARIS, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, continued its commitment to accelerating justice around the globe with a leading presence at Milipol, the preeminent global law enforcement and homeland security event held November 14-17, 2023 in Paris. In addition to serving as one of the show’s sponsors, Cellebrite’s senior leadership, sales and service teams engaged with law enforcement professionals from more than 100 countries to discuss industry best practices and showcase recent innovations and emerging digital solutions. Highlights of Cellebrite’s show presence include: EMEA Senior Leadership convening with dozens of law enforcement professionals to discuss best practices and
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept28.11.2023 14:27:00 CET | Press release
Proof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cancers by targeting a novel class of antigensBroad Applicability – The vaccine concept holds tremendous potential, offering broad applicability and promising benefits for patients with hematological malignancies COPENHAGEN, Denmark, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, proudly announces the presentation of its novel precision vaccine concept at the 65th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, California, from December 9-12, 2023. Selected for an Oral Presentation – Evaxion has been chosen for an oral presentation from a competitive pool of >5000 submitted abstracts. The presentation will unveil a breakthrough achievement using the Company’s proprietary AI target dis
Finanskalender 2024 for Djurslands Bank A/S28.11.2023 14:24:56 CET | pressemeddelelse
Fondsbørsmeddelelse 18/2023 I henhold til gældende oplysningsforpligtelser følger hermed finanskalender med forventede datoer for offentliggørelser m.m. for regnskabsåret 2024. 20. februar 2024Årsrapport for 202319. marts 2024Ordinær generalforsamling *)15. maj 2024Kvartalsrapport for 1. kvartal 202416. august 2024Halvårsrapport for 1. halvår 2024 8. november 2024 Kvartalsrapport for 1. – 3. kvartal 2024 *) Jævnfør vedtægternes §7 stk. 2 skal forslag fra aktionærerne være indleveret skriftligt til bestyrelsen senest 6 uger før generalforsamlingens afholdelse, svarende til den 5. februar 2024, for at komme til behandling på generalforsamlingen. Med venlig hilsen Djurslands Bank Sigurd Simmelsgaard Adm. direktør Vedhæftet fil 18-2023 Finanskalender 2024 Djurslands Bank
TRESU Investment Holding A/S – Announcement of Q3 2023 Interim Report28.11.2023 14:07:53 CET | Press release
TRESU INVESTMENT HOLDING A/S ANNOUNCEMENT NO. 08.2023 28.11.2023 TRESU Investment Holding A/S – Announcement of Q3 2023 Interim Report Tresu Investment Holding A/S today publishes the Q3 2023 Interim Report and presentation of the financial results. We are pleased to invite you to the financial results call, which is being held Friday, 1 December 2023, at 12:30am CET. The Interim Report will be presented by Stephan Plenz, CEO and Torben Børsting, CFO. After the presentations there will be an opportunity for Q+A. A recording of the results call will be made available for four hours on the TRESU IR website. To register for the investor call, please send an e-mail to Financial manager at TRESU A/S Finn Holm no later than 30 November 2023 9am CET - email@example.com Stephan plenz CEO, TRESU For further details, please contact: CEO, Stephan Plenz, phone: +45 2194 5480 CFO, Torben Børsting, phone: +45 5130 2780 Attachments Quarterly reporting - 2023 Q3Tresu Investment Holding interim report 2023